A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

May 8, 2025

Study Completion Date

May 8, 2025

Conditions
Chronic Inducible Urticaria
Interventions
DRUG

Oral EVO756

Oral EVO756, once daily

Trial Locations (18)

10128

OptiSkin Medical, New York

15241

Allergy and Clinical Immunology Associates, Pittsburgh

21162

Chesapeake Clinical Research, Inc, White Marsh

31406

Aeroallergy Research Laboratories of Savannah, Inc., Savannah

33607

Advanced Clinical Research Institute, Tampa

35244

Cahaba Dermatology & Skin Health Center, LLC, Birmingham

43209

Bexley Dermatology Research, Bexley

46168

Indiana Clinical Trials Center, P.C., Plainfield

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

47150

Southern Indiana Clinical Trials, New Albany

58013

Red River Research Partners, Fargo

70809

DelRicht Research, Baton Rouge

73120

Allergy, Asthma, and Clinical Research Center, Oklahoma City

78660

Austin Institute for Clinical Research, Pflugerville

83706

Treasure Valley Medical Research, Boise

90025

California Allergy and Asthma Medical Group, Los Angeles

92121

West Dermatology Research Center, San Diego

95815

Integrative Skin Science and Research, Sacramento

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Evommune, Inc.

INDUSTRY

NCT06603220 - A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria | Biotech Hunter | Biotech Hunter